Research analyst, medium-term horizon, biotech, small-cap

Zalicus To Be Acquired By Epirus Biopharma

On April 16, 2014, Zalicus Inc. (ZLCS) announced that it has entered into a definitive agreement with Epirus Biopharmaceuticals, a privately-held biopharma company focused on the global development and commercialization of biosimilar monoclonal antibodies. The merger will create a Nasdaq-listed, publicly traded company focused on building a global biosimilar enterprise. We discuss Epirus, its pipeline, and how Zalicus fits into the new organization below. However, first let's discuss the terms of the agreement.

The percentage of the combined company that Zalicus stockholders will own as of the closing of the merger is subject to adjustment based on the level of Zalicus' net cash at the closing date. The ownership of current Zalicus stockholders will be:

    Approximately 19% of the combined...
Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details